FDA slaps Pfizer for Zyvox professional ad

Share this article:
The Food and Drug Administration slapped Pfizer with a warning letter over a four-page journal ad for its Zyvox antibiotic.

The agency's Division of Drug Marketing, Advertising and Communications (DDMAC) said the ad failed to meet the fair balance requirement by omitting risk information, expanded the indication of the drug and made unsubstantiated claims of superiority to vancomycin for the treatment of pneumonia based on insufficient studies.

The letter, dated July 20, reads in part, "Your misleading promotion of Zyvox, and in particular, your unsubstantiated implied claims regarding its superiority to vancomycin, poses serious public health and safety concerns because of its potential to result in the inappropriate use of Zyvox, which is associated with increased toxicity relative to vancomycin."

Zyvox professional advertising is handled by Cline, Davis & Mann. 
Share this article:
close

Next Article in News

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union